WallStSmart

Caring Brands, Inc. Common Stock (CABR)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 1714092427% more annual revenue ($72.25B vs $4,215). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).

CABR

Avoid

13

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 5/9Altman Z: 6.92

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CABR1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
6.9210/10

Safe zone — low bankruptcy risk

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$862.01B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.8%10/10

Earnings expanding 169.8% YoY

Areas to Watch

CABR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.61M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-217.1%2/10

ROE of -217.1% — below average capital efficiency

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
34.3x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
32.9x2/10

Trading at 32.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CABR

The strongest argument for CABR centers on Altman Z-Score.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : CABR

The primary concerns for CABR are EPS Growth, Market Cap, Profit Margin.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

CABR profiles as a value stock while LLY is a growth play — different risk/reward profiles.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (78/100 vs 13/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caring Brands, Inc. Common Stock

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Caring Brands, Inc., a wellness consumer products company, provides over-the-counter and cosmetic consumer products. The company is headquartered in Fort Pierce, Florida.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?